|
Researchers at the Scripps Research Institute advance heteorcylic chemistry trhough new reagents and reaction-tracking techniques.
Jun 2, 2013
By:
Patricia Van Arnum
Researchers at the Scripps Research Institute advance heteorcylic chemistry trhough new reagents and reaction-tracking techniques.
|
A recent study of computer-created and natural proteins suggests the number of sites where small-molecule drugs can bind to proteins is limited, thereby narrowing how to mitigate side effects through drug design.
Jun 2, 2013
By:
Patricia Van Arnum
A recent study of computer-created and natural proteins suggests the number of sites where small-molecule drugs can bind to proteins is limited, thereby narrowing how to mitigate side effects through drug design.
|
The draft guidance describes how quality agreements can be used to delineate the responsibilities of contract manufacturers involved in the cGMP manufacture of APIs and finished drug products.
May 28, 2013
By:
Patricia Van Arnum
The draft guidance describes how quality agreements can be used to delineate the responsibilities of contract manufacturers involved in the cGMP manufacture of APIs and finished drug products.
|
Company receives notice from FDA for not fully investigating foreign particles in APIs and finished products made from its facility in Ingelheim am Rhein, Germany.
May 28, 2013
By:
Patricia Van Arnum
Company receives notice from FDA for not fully investigating foreign particles in APIs and finished products made from its facility in Ingelheim am Rhein, Germany.
|
The Global Vaccine Action plan maps out a strategy to increase access and R&D for vaccines.
May 3, 2013
By:
Patricia Van Arnum
The Global Vaccine Action plan maps out a strategy to increase access and R&D for vaccines.
|
Financing to biotech companies in North American and Europe declined in 2012 as debt funding decreased and the IPO market remained weak.
May 3, 2013
By:
Patricia Van Arnum
Financing to biotech companies in North American and Europe declined in 2012 as debt funding decreased and the IPO market remained weak.
|
Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Sanofi, and Roche are among the companies expanding biologic-based manufacturing capacity.
May 3, 2013
By:
Patricia Van Arnum
Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Sanofi, and Roche are among the companies expanding biologic-based manufacturing capacity.
|
|
The rejection by India's Supreme Court on Novartis' Glivec/Gleevec (imatinib mesylate) and other recent case law raise important issues on patent strategies for solid forms.
May 2, 2013
By:
Patricia Van Arnum
The rejection by India's Supreme Court on Novartis' Glivec/Gleevec (imatinib mesylate) and other recent case law raise important issues on patent strategies for solid forms.
|
Solid-state chemistry is an important part of drug development, and public research is advancing the field.
May 2, 2013
By:
Patricia Van Arnum
Solid-state chemistry is an important part of drug development, and public research is advancing the field.
|
|
